Entrada Therapeutics (TRDA) announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. Since August 2024, Dr. Radhakrishnan has served as Executive Partner at Sofinnova Investments, a European venture capital firm focused on life sciences
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRDA:
- Buy Rating for Entrada Therapeutics: Strategic Positioning and Regulatory Advances in Exon-Skipping Therapeutics
- Entrada Therapeutics receives authorization from in EU to start ELEVATE-45-201
- Entrada Therapeutics price target lowered to $21 from $23 at Roth Capital
- Entrada Therapeutics: Strategic Advancements in DMD Pipeline Drive Buy Rating
- Entrada Therapeutics reports Q1 EPS (42c), consensus (77c)